Literature DB >> 27639192

Changes in blood microbiota profiles associated with liver fibrosis in obese patients: A pilot analysis.

Benjamin Lelouvier1, Florence Servant1, Sandrine Païssé1, Anne-Claire Brunet1,2, Salah Benyahya1, Matteo Serino3, Carine Valle1, Maria Rosa Ortiz4, Josep Puig5, Michael Courtney1, Massimo Federici6, José-Manuel Fernández-Real4, Rémy Burcelin1,3, Jacques Amar1,3,7.   

Abstract

The early detection of liver fibrosis among patients with nonalcoholic fatty liver disease (NAFLD) is an important clinical need. In view of the suggested role played by bacterial translocation in liver disease and obesity, we sought to investigate the relationship between blood microbiota and liver fibrosis (LF) in European cohorts of patients with severe obesity. We carried out a cross-sectional study of obese patients, well characterized with respect to the severity of the NAFLD, in the cohort FLORINASH. This cohort has been divided into a discovery cohort comprising 50 Spanish patients and then in a validation cohort of 71 Italian patients. Blood bacterial DNA was analyzed both quantitatively by 16S ribosomal DNA (rDNA) quantitative polymerase chain reaction and qualitatively by 16S rDNA targeted metagenomic sequencing and functional metagenome prediction. Spanish plasma bile acid contents were analyzed by liquid chromatography/mass spectrometry. The 16S rDNA concentration was significantly higher in patients of the discovery cohort with LF. By 16S sequencing, we found specific differences in the proportion of several bacterial taxa in both blood and feces that correlate with the presence of LF, thus defining a specific signature of the liver disease. Several secondary/primary bile acid ratios were also decreased with LF in the discovery cohort. We confirmed, in the validation cohort, the correlation between blood 16S rDNA concentration and LF, whereas we did not confirm the specific bacterial taxa signature, despite a similar trend in patients with more-severe fibrosis.
CONCLUSION: Changes in blood microbiota are associated with LF in obese patients. Blood microbiota analysis provides potential biomarkers for the detection of LF in this population. (Hepatology 2016;64:2015-2027).
© 2016 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2016        PMID: 27639192     DOI: 10.1002/hep.28829

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  91 in total

1.  Blood Microbiome Profile in CKD : A Pilot Study.

Authors:  Neal B Shah; Andrew S Allegretti; Sagar U Nigwekar; Sahir Kalim; Sophia Zhao; Benjamin Lelouvier; Florence Servant; Gloria Serena; Ravi Ishwar Thadhani; Dominic S Raj; Alessio Fasano
Journal:  Clin J Am Soc Nephrol       Date:  2019-04-08       Impact factor: 8.237

2.  The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis.

Authors:  Puneet Puri; Suthat Liangpunsakul; Jeffrey E Christensen; Vijay H Shah; Patrick S Kamath; Gregory J Gores; Susan Walker; Megan Comerford; Barry Katz; Andrew Borst; Qigui Yu; Divya P Kumar; Faridoddin Mirshahi; Svetlana Radaeva; Naga P Chalasani; David W Crabb; Arun J Sanyal
Journal:  Hepatology       Date:  2018-02-22       Impact factor: 17.425

Review 3.  Gut microbiome changes in Nonalcoholic fatty liver disease & alcoholic liver disease.

Authors:  Eric K Kwong; Puneet Puri
Journal:  Transl Gastroenterol Hepatol       Date:  2021-01-05

Review 4.  Can intestinal microbiota and circulating microbial products contribute to pulmonary arterial hypertension?

Authors:  Thenappan Thenappan; Alexander Khoruts; Yingjie Chen; E Kenneth Weir
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-09-06       Impact factor: 4.733

Review 5.  Advances in non-invasive biomarkers for the diagnosis and monitoring of non-alcoholic fatty liver disease.

Authors:  Michelle T Long; Sanil Gandhi; Rohit Loomba
Journal:  Metabolism       Date:  2020-05-05       Impact factor: 8.694

Review 6.  Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in HIV.

Authors:  Jürgen Kurt Rockstroh
Journal:  Curr HIV/AIDS Rep       Date:  2017-04       Impact factor: 5.071

Review 7.  Contribution of the commensal microbiota to atherosclerosis and arterial thrombosis.

Authors:  Klytaimnistra Kiouptsi; Christoph Reinhardt
Journal:  Br J Pharmacol       Date:  2018-09-25       Impact factor: 8.739

8.  Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease.

Authors:  Rohit Loomba; Victor Seguritan; Weizhong Li; Tao Long; Niels Klitgord; Archana Bhatt; Parambir Singh Dulai; Cyrielle Caussy; Richele Bettencourt; Sarah K Highlander; Marcus B Jones; Claude B Sirlin; Bernd Schnabl; Lauren Brinkac; Nicholas Schork; Chi-Hua Chen; David A Brenner; William Biggs; Shibu Yooseph; J Craig Venter; Karen E Nelson
Journal:  Cell Metab       Date:  2017-05-02       Impact factor: 27.287

Review 9.  Liver tissue microbiota in nonalcoholic liver disease: a change in the paradigm of host-bacterial interactions.

Authors:  Silvia Sookoian; Carlos J Pirola
Journal:  Hepatobiliary Surg Nutr       Date:  2021-06       Impact factor: 7.293

Review 10.  Gut microbiome and cardiometabolic risk.

Authors:  Ben Arpad Kappel; Massimo Federici
Journal:  Rev Endocr Metab Disord       Date:  2019-12       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.